Xponance, Inc. Geron Corp Transaction History

Xponance, Inc.

$10.2 Billion
Q3 2024

A detailed history of Xponance, Inc. transactions in Geron Corp stock. As of the latest transaction made, Xponance, Inc. holds 37,572 shares of GERN stock, worth $152,918. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,572

Previous 36,473 3.01%

Holding current value

$152,918

Previous $154,000 10.39%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.17 - $4.99 $4,582 - $5,484	1,099 Added 3.01%	37,572 $170,000
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $17,635 - $28,957	5,689 Added 18.48%	36,473 $154,000
Q1 2024 May 13, 2024	SELL	$1.75 - $3.44 $434 - $853	-248 Reduced 0.8%	30,784 $101,000
Q4 2023 Jan 31, 2024	BUY	$1.74 - $2.31 $2,958 - $3,927	1,700 Added 5.8%	31,032 $65,000
Q2 2023 Jul 13, 2023	BUY	$1.97 - $3.69 $10,429 - $19,534	5,294 Added 22.02%	29,332 $94,000
Q1 2023 Apr 17, 2023	BUY	$2.14 - $3.4 $7,081 - $11,250	3,309 Added 15.96%	24,038 $52,000
Q4 2022 Jan 23, 2023	BUY	$2.03 - $2.42 $854 - $1,018	421 Added 2.07%	20,729 $0
Q3 2022 Oct 24, 2022	BUY	$1.67 - $2.94 $1,392 - $2,451	834 Added 4.28%	20,308 $48,000
Q2 2022 Aug 02, 2022	BUY	$1.19 - $1.65 $6,114 - $8,477	5,138 Added 35.84%	19,474 $30,000
Q1 2022 Apr 20, 2022	SELL	$0.99 - $1.6 $142 - $230	-144 Reduced 0.99%	14,336 $19,000
Q4 2021 Jan 31, 2022	BUY	$1.22 - $1.72 $309 - $436	254 Added 1.79%	14,480 $18,000
Q3 2021 Nov 05, 2021	SELL	$1.2 - $1.5 $2,643 - $3,304	-2,203 Reduced 13.41%	14,226 $19,000
Q2 2021 Aug 12, 2021	BUY	$1.25 - $1.83 $20,536 - $30,065	16,429 New	16,429 $23,000

Others Institutions Holding GERN

# of Institutions

275

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.54B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Xponance, Inc. with notifications on news.

Account